Depending on the classification, risk-adapted follow-up is performed with calculation of the tumour marker doubling time (i.e. Ctn/CEA) and imaging to detect possible tumour growth and, if necessary, adjustment of the risk group (18, 19). The gene discussed is CEACAM5; the disease is neoplasm.